Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,750 | 331 | 98.7% |
| Education | $73.34 | 3 | 1.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $18.04 | 1 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $776.86 | 54 | $0 (2024) |
| ABBVIE INC. | $742.97 | 46 | $0 (2024) |
| UCB, Inc. | $557.33 | 18 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $405.21 | 22 | $0 (2024) |
| Biogen, Inc. | $398.97 | 13 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $396.56 | 19 | $0 (2024) |
| SK Life Science, Inc. | $296.83 | 12 | $0 (2024) |
| Genentech USA, Inc. | $294.26 | 12 | $0 (2024) |
| Allergan, Inc. | $285.97 | 13 | $0 (2022) |
| PFIZER INC. | $262.35 | 13 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,441 | 66 | PFIZER INC. ($239.06) |
| 2023 | $1,359 | 59 | SK Life Science, Inc. ($169.08) |
| 2022 | $1,193 | 72 | ABBVIE INC. ($307.39) |
| 2021 | $1,123 | 63 | AbbVie Inc. ($177.94) |
| 2020 | $405.87 | 20 | Allergan, Inc. ($90.97) |
| 2019 | $619.46 | 23 | Biogen, Inc. ($123.57) |
| 2018 | $216.44 | 12 | Medtronic USA, Inc. ($55.10) |
| 2017 | $482.41 | 20 | UCB, Inc. ($179.07) |
All Payment Transactions
335 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | In-kind items and services | $21.61 | General |
| Category: Neuroscience | ||||||
| 12/12/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $23.47 | General |
| Category: Neuropsychiatry | ||||||
| 11/26/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $25.36 | General |
| 11/21/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $22.75 | General |
| Category: Neurology | ||||||
| 11/21/2024 | PFIZER INC. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $22.20 | General |
| Category: PAIN | ||||||
| 11/20/2024 | PFIZER INC. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $16.26 | General |
| Category: PAIN | ||||||
| 11/15/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $29.08 | General |
| Category: Neuropsychiatry | ||||||
| 11/15/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $2.70 | General |
| Category: Neuropsychiatry | ||||||
| 11/14/2024 | Merz Pharmaceuticals, LLC | Xeomin (Biological), INBRIJA | Food and Beverage | In-kind items and services | $22.77 | General |
| Category: Musculoskeletal | ||||||
| 11/08/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $34.62 | General |
| Category: Rare Disease | ||||||
| 10/22/2024 | PFIZER INC. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $23.98 | General |
| Category: PAIN | ||||||
| 10/17/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $21.82 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 10/16/2024 | Chiesi USA, Inc. | — | Food and Beverage | In-kind items and services | $65.00 | General |
| 10/09/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $31.64 | General |
| Category: Neuropsychiatry | ||||||
| 10/09/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $26.32 | General |
| Category: PAIN | ||||||
| 10/03/2024 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $34.62 | General |
| Category: Neurology | ||||||
| 10/01/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $31.97 | General |
| Category: Neuropsychiatry | ||||||
| 10/01/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $5.80 | General |
| Category: Neurology | ||||||
| 10/01/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $5.12 | General |
| Category: Neurology | ||||||
| 09/27/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $22.88 | General |
| Category: Neuroscience | ||||||
| 09/21/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $14.29 | General |
| Category: PAIN | ||||||
| 09/19/2024 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $33.30 | General |
| Category: Neurology | ||||||
| 09/19/2024 | ABBVIE INC. | BOTOX (Biological), QULIPTA | Food and Beverage | In-kind items and services | $18.95 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 09/19/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $16.25 | General |
| Category: Rare Disease | ||||||
| 09/18/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $18.63 | General |
| Category: Central Nervous System | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 1,148 | 1,874 | $467,312 | $186,689 |
| 2022 | 14 | 1,043 | 1,590 | $403,971 | $158,788 |
| 2021 | 12 | 905 | 1,375 | $324,966 | $131,730 |
| 2020 | 15 | 875 | 5,863 | $348,963 | $134,095 |
All Medicare Procedures & Services
53 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 216 | 566 | $128,063 | $57,305 | 44.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 174 | 300 | $72,000 | $29,347 | 40.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 198 | 361 | $57,031 | $24,177 | 42.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 162 | 166 | $73,030 | $22,495 | 30.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 97 | 138 | $44,480 | $19,604 | 44.1% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Facility | 2023 | 140 | 155 | $18,414 | $7,308 | 39.7% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 22 | 36 | $21,670 | $6,204 | 28.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 33 | 33 | $15,040 | $5,997 | 39.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 56 | 56 | $16,578 | $5,575 | 33.6% |
| 95720 | Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional | Facility | 2023 | 14 | 22 | $9,512 | $3,865 | 40.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 24 | 24 | $8,724 | $3,510 | 40.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 12 | 17 | $2,771 | $1,300 | 46.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 171 | 409 | $92,540 | $35,505 | 38.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 172 | 276 | $66,240 | $28,676 | 43.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 120 | 123 | $54,113 | $19,783 | 36.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 164 | 318 | $50,238 | $19,196 | 38.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 76 | 90 | $29,009 | $13,613 | 46.9% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 76 | 76 | $22,499 | $8,499 | 37.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 49 | 49 | $22,332 | $8,476 | 38.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 49 | 49 | $17,811 | $6,727 | 37.8% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Facility | 2022 | 85 | 88 | $10,454 | $4,327 | 41.4% |
| 95720 | Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional | Facility | 2022 | 13 | 24 | $10,377 | $4,261 | 41.1% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 13 | 20 | $12,039 | $3,533 | 29.3% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2022 | 25 | 38 | $8,011 | $3,233 | 40.4% |
| 95909 | Nerve conduction, 5-6 studies | Office | 2022 | 14 | 14 | $4,853 | $1,628 | 33.5% |
About Dr. Nima Ramezan Arab, M.D
Dr. Nima Ramezan Arab, M.D is a Neurology healthcare provider based in Los Alamitos, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1699705772.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nima Ramezan Arab, M.D has received a total of $6,841 in payments from pharmaceutical and medical device companies, with $1,441 received in 2024. These payments were reported across 335 transactions from 48 companies. The most common payment nature is "Food and Beverage" ($6,750).
As a Medicare-enrolled provider, Ramezan Arab has provided services to 3,971 Medicare beneficiaries, totaling 10,702 services with total Medicare billing of $611,302. Data is available for 4 years (2020–2023), covering 53 distinct procedure/service records.
Practice Information
- Specialty Neurology
- Location Los Alamitos, CA
- Active Since 07/04/2006
- Last Updated 02/19/2017
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1699705772
Products in Payments
- KESIMPTA (Drug) $700.17
- NURTEC ODT (Drug) $523.90
- UBRELVY (Drug) $395.51
- INGREZZA (Drug) $324.45
- BOTOX (Biological) $284.49
- QULIPTA (Drug) $223.56
- TYSABRI (Biological) $213.78
- Briviact (Drug) $209.33
- ULTOMIRIS (Biological) $201.78
- OCREVUS (Biological) $139.97
- ZEPOSIA (Drug) $136.29
- AJOVY (Biological) $128.59
- BRILINTA (Drug) $124.98
- NUPLAZID (Drug) $124.17
- Vimpat (Drug) $115.56
- XARELTO (Drug) $108.80
- EMGALITY (Drug) $102.78
- Ocrevus (Biological) $91.55
- Aimovig (Biological) $87.78
- SOLIRIS (Biological) $82.98
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Los Alamitos
Dr. Nirav Patel, M.d, M.D
Neurology — Payments: $848,036
Dr. Omid Omidvar, M.d, M.D
Neurology — Payments: $33,376
Dr. David Rosenberg, M.d, M.D
Neurology — Payments: $10,685
Yamin Shwe, Md, MD
Neurology — Payments: $4,909
Alan Cohen, M.d, M.D
Neurology — Payments: $3,717
Dr. Mohan Tadikonda, M.d, M.D
Neurology — Payments: $247.80